Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 6,080 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matched control Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease

NCT03351738
View directory record Official record
Conditions
Stable Coronary Heart Disease
Interventions
MEDI5884, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
45 Years to 80 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
23
States / cities
Anniston, Alabama • Huntsville, Alabama • El Cajon, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Single-Dose Escalation Study of PF-04308515 in Healthy Volunteers

NCT00990015
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF-04308515, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 1, 2010 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

NCT04096326
View directory record Official record
Conditions
Glabellar Lines
Interventions
AGN-151586, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Fremont, California • Santa Monica, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

NCT03429543
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Metformin, Insulin, Placebo, Linagliptin, Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
10 Years to 17 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
44
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cognitive and Emotional Skills to Aid Smoking Prevention

NCT03058991
View directory record Official record
Conditions
Tobacco Smoking
Interventions
Distress Tolerance Intervention, Working Memory Intervention, Control Informational Intervention
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
12 Years to 16 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 30, 2026, 1:46 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety

NCT00364533
View directory record Official record
Conditions
Arthroplasty
Interventions
Tapentadol IR (CG5503), Placebo, Oxycodone HCL IR
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
45
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

NCT01553747
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
232
States / cities
Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 189 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

NCT02947347
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Ibrutinib Oral Capsule, Placebo, Rituximab
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
60 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
25
States / cities
Mobile, Alabama • Duarte, California • Santa Barbara, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 30, 2026, 1:46 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Trial of Inflammatory Markers, Depressive Symptoms, and Heart Disease

NCT00208117
View directory record Official record
Conditions
Depression, Coronary Artery Disease (CAD), Acute Coronary Syndrome (ACS)
Interventions
Sertraline (Zoloft), Simvastatin (Zocor)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 30, 2026, 1:46 PM EDT
Withdrawn Phase 3 Interventional

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

NCT02392676
View directory record Official record
Conditions
Platinum Sensitive Relapsed Ovarian Cancer
Interventions
OLAPARIB, PLACEBO
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 96 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes

NCT00132678
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperdal Consta, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
14
States / cities
Little Rock, Arkansas • La Mesa, California • National City, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of FTX-6058

NCT04586985
View directory record Official record
Conditions
Healthy Adult Subjects, Sickle Cell Disease
Interventions
FTX-6058/placebo oral capsule(s), FTX-6058 - Two Dosing Periods, FTX-6058 / Midazolam Syrup
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants

NCT03224325
View directory record Official record
Conditions
Healthy
Interventions
TAK-831 Tablet T2, Placebo, TAK-831 Suspension
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 30, 2026, 1:46 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of a Fermented Dairy Protein With Prebiotic Fiber on GI Complaints

NCT06946017
View directory record Official record
Conditions
Digestive Health, Quality of Life
Interventions
Fermented dairy protein with prebiotic fiber supplement, Control placebo
Dietary Supplement
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 50 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 30, 2026, 1:46 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation

NCT02559817
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C, Linaclotide Approved Adult Dose, Matching Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
46
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Oct 30, 2026, 1:46 PM EDT
Enrolling by invitation Phase 2 Interventional

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1

NCT07217665
View directory record Official record
Conditions
PSP - Progressive Supranuclear Palsy
Interventions
AADvac1, Matching Placebo
Biological
Lead sponsor
Adam Boxer
Other
Eligibility
41 Years to 86 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Phase 2 Interventional

Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

NCT06836063
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Ropanicant, Placebo
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
35
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers

NCT03146416
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Evinacumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 30, 2026, 1:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nationwide Study of Firearm Violence Prevention Tactics and Policies in K-12 Schools

NCT05552716
View directory record Official record
Conditions
Violence
Interventions
School safety tactics and policies
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
648 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.

NCT00790192
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone, Quetiapine XR, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
29
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 30, 2026, 1:46 PM EDT
Terminated Phase 2 Interventional Results available

Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study

NCT01934192
View directory record Official record
Conditions
Gastroparesis
Interventions
GSK962040 50 mg, Metoclopramide 10 mg, Placebo NG, Placebo IV
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Aurora, Colorado • Augusta, Georgia • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)

NCT05469464
View directory record Official record
Conditions
Atopic Dermatitis, Skin Diseases
Interventions
Orismilast modified release tablets, Placebo
Drug
Lead sponsor
UNION therapeutics
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Canoga Park, California • Fountain Valley, California • Inglewood, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects

NCT03310463
View directory record Official record
Conditions
Acinetobacter Baumannii Infection
Interventions
ETX2514SUL
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Lakewood, Colorado • Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects

NCT01813448
View directory record Official record
Conditions
Pharmacokinetics of Fidaxomicin, Healthy Subjects
Interventions
Fidaxomicin, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
20 Years to 55 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 30, 2026, 1:46 PM EDT